AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|
10.9 C
New York
Monday, October 19, 2026

Tag: autoimmune disease

newssourceFORcompanycontentinformation1releasesmarket

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to...

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Ad hoc announcement pursuant to Art. 53 LR

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAutoimmune disease

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers